Overview

Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC

Status:
Unknown status

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

To explore the efficacy and safety of pyrotinib combined with docetaxel regimen in the first-line treatment of HER2-positive metastatic breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Zhejiang Cancer Hospital

Collaborator:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Docetaxel
Maleic acid